Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix Provides Update on Nellix PMA Process

Endologix Appoints Matthew Thompson, M.D., as Chief Medical Officer

Endologix Reports Positive Clinical Data from Ovation® LIFE (Least Invasive Fast-Track EVAR) Study

Endologix Reports Positive Clinical Data on the Nellix EVAS System from a Multicenter Study in Italy

Endologix Reports Positive Clinical Data from the Nellix EVAS FORWARD-IDE Study